利伐沙班联合阿司匹林或单药预防CABG术后早期桥血管闭塞:COMPASS-CABG研究
COMPASS-CABG预设亚组纳入1448例CABG术后4-14天患者,随机接受利伐沙班2.5mg bid联合阿司匹林100mg qd、利伐沙班5mg bid单药或阿司匹林100mg qd单药,主要终点为术后1年CTA诊断的桥血管失败。联合治疗和利伐沙班单药均未较阿司匹林单药降低桥血管失败率;联合治疗MACE数值上更少但未达统计学显著。
要点
- 利伐沙班联合阿司匹林未降低CABG术后1年桥血管失败率(9.1% vs 8.0%,OR 1.13,p=0.45)。
- 利伐沙班5mg bid单药未降低桥血管失败率(7.8% vs 8.0%,OR 0.95,p=0.75)。
- 联合治疗MACE数值更少(2.4% vs 3.5%,HR 0.69,p=0.34),但未达统计学显著。
核心结论
- 与阿司匹林单药相比,利伐沙班2.5mg bid联合阿司匹林或利伐沙班5mg bid单药均未减少CABG术后桥血管失败。
- 联合治疗MACE的降低幅度与主COMPASS试验中观察到的相似。
研究设计与样本
- COMPASS试验预设亚组,纳入1448例CABG术后4-14天患者。
- 随机分为利伐沙班联合阿司匹林、利伐沙班单药或阿司匹林单药三组。
- 主要终点为术后1年CTA诊断的桥血管失败。
主要发现
- 联合治疗组桥血管失败113例(9.1%),阿司匹林组91例(8.0%),OR 1.13(95%CI 0.82-1.57,p=0.45)。
- 利伐沙班单药组桥血管失败92例(7.8%),阿司匹林组92例(8.0%),OR 0.95(95%CI 0.67-1.33,p=0.75)。
- 联合治疗组MACE 12例(2.4%),阿司匹林组16例(3.5%),HR 0.69(95%CI 0.33-1.47,p=0.34)。
- 利伐沙班单药组MACE 16例(3.3%),阿司匹林组16例(3.5%),HR 0.99(95%CI 0.50-1.99,p=0.98)。
- 随机化后30天内无致命性出血或心包填塞。
临床怎么用
- CABG术后早期使用利伐沙班联合阿司匹林或利伐沙班单药不能以预防桥血管失败为目的。
- 联合治疗对MACE的潜在获益未达统计学显著,需结合主COMPASS试验结果综合判断。
局限性
- 本研究为COMPASS预设亚组,样本量1448例,可能不足以检出桥血管失败或MACE的显著差异。
- 桥血管失败以术后1年CTA诊断,未报告更早期或更晚期桥血管失败情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with recent coronary artery bypass graft (CABG) surgery are at risk for early graft failure, which is associated with a risk of myocardial infarction and death. In the COMPASS (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS) trial, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced the primary major adverse cardiovascular events (MACE) outcome of cardiovascular death, stroke, or myocardial infarction. Rivaroxaban 5 mg twice daily alone did not significantly reduce MACE. OBJECTIVES: This pre-planned substudy sought to determine whether the COMPASS treatments are more effective than aspirin alone for preventing graft failure and MACE after CABG surgery. METHODS: The substudy randomized 1,448 COMPASS trial patients 4 to 14 days after CABG surgery to receive the combination of rivaroxaban plus aspirin, rivaroxaban alone, or aspirin alone. The primary outcome was graft failure, diagnosed by computed tomography angiogram 1 year after surgery. RESULTS: The combination of rivaroxaban and aspirin and the regimen of rivaroxaban alone did not reduce the graft failure rates compared with aspirin alone (combination vs. aspirin: 113 [9.1%] vs. 91 [8.0%] failed grafts; odds ratio [OR]: 1.13; 95% confidence interval [CI]: 0.82 to 1.57; p = 0.45; rivaroxaban alone vs. aspirin: 92 [7.8%] vs. 92 [8.0%] failed grafts; OR: 0.95; 95% CI: 0.67 to 1.33; p = 0.75). Compared with aspirin, the combination was associated with fewer MACE (12 [2.4%] vs. 16 [3.5%]; hazard ratio [HR]: 0.69; 95% CI: 0.33 to 1.47; p = 0.34), whereas rivaroxaban alone was not (16 [3.3%] vs. 16 [3.5%]; HR: 0.99, CI: 0.50 to 1.99; p = 0.98). There was no fatal bleeding or tamponade within 30 days of randomization. CONCLUSIONS: The combination of rivaroxaban 2.5 mg twice daily plus aspirin or rivaroxaban 5 mg twice daily alone compared with aspirin alone did not reduce graft failure in patients with recent CABG surgery, but the combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with similar reductions in MACE, as observed in the larger COMPASS trial. (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS [COMPASS]; NCT01776424).
引用
- Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019. PMID: 30654882. doi:10.1016/j.jacc.2018.10.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。